On February 4, 2026 Defence Therapeutics Inc. ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, reported that it will present at World ADC Europe 2026, taking place February 23–26, 2026, in London, UK.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Defence will showcase its proprietary Accum platform, a breakthrough intracellular delivery technology designed to actively transport biologic payloads to their intended intracellular and nuclear targets, unlocking the full potential of antibody-drug conjugates ("ADCs") and other complex cancer biologics by increasing intracellular potency and reducing the doses required to achieve therapeutic efficacy.
"At Defence, our mission is to transform advanced biologics into safer, more effective first-line cancer therapies through precision intracellular delivery," said Sébastien Plouffe, CEO of Defence Therapeutics. "World ADC Europe is a premier global forum to engage with innovators and potential partners who share our vision of a future where every cancer therapy reaches its full potential."
This announcement is being made on World Cancer Day, underscoring Defence’s commitment to accelerating next-generation cancer therapies that address critical unmet medical needs. "On World Cancer Day, we are reminded of the urgency to bring smarter, more precise cancer treatments to patients," added Mr. Plouffe. "Accum has the potential to help cancer therapies reach their full potential and deliver better outcomes for patients."
At the conference, Defence aims to engage with pharmaceutical and biotechnology companies and advance strategic partnering discussions around co-developing Accum-enabled ADCs and precision oncology biologics, leveraging Accum to enhance intracellular delivery and therapeutic performance. To explore partnering opportunities or schedule a meeting, please contact [email protected].
(Press release, Defence Therapeutics, FEB 4, 2026, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-to-present-at-the-world-adc-europe-2026-showcasing-accum-precision-intracellular-drug-delivery-platform [SID1234662467])